登录 注册 会员服务 联系我们

New Challenges in Kidney Cancer Management: Integration of Surgery and Novel Therapies

  • Published:2015-03 Issue:3 Volume:16 Page:
  • ISSN:1527-2729
  • Container-title:Current Treatment Options in Oncology
  • language:en
  • Short-container-title:Curr. Treat. Options in Oncol.

Author:

Puente Vázquez Javier,Alonso Gordoa T.,Moreno J.,Poma L.,Diaz Rubio E.,Gomez A.,Blazquez J.,Gonzalez Larriba J. L.

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Oncology

Reference53 articles.

1. Thillai K, Allan S, Powles T, Rudman S, Chowdhury S. Neoadjuvant and adjuvant treatment of renal cell carcinoma. Expert Rev Anticancer Ther. 2012;12(6):765–76.

2. Heng DYC, Xie W, Regan MM, Warren MA, Golshayan AR, Sahi C, et al. Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study. J Clin Oncol. 2009;27(34):5794–9. The authors present a prognostic model composed of six readily available clinical parameters that are able to stratify patients into favorable, intermediate and poor prognosis group.

3. Krabbe L-M, Haddad AQ, Westerman ME, Margulis V. Surgical management of metastatic renal cell carcinoma in the era of targeted therapies. World J Urol. 2014;32(3):615–22.

4. Tsao C-K, Small AC, Kates M, Moshier EL, Wisnivesky JP, Gartrell BA, et al. Cytoreductive nephrectomy for metastatic renal cell carcinoma in the era of targeted therapy in the United States: a SEER analysis. World J Urol. 2012;31(6):1535–9. The Surveillance, Epidemiology and End Results registry was used to identify patients with confirmed stage IV renal cell carcinoma between 2001 and 2008. The authors conclude that the use of cytoreductive nephrectomy in the United States has declined in the VEGFR-TKi era.

5. Culp SH, Tannir NM, Abel EJ, Margulis V, Tamboli P, Matin SF, et al. Can we better select patients with metastatic renal cell carcinoma for cytoreductive nephrectomy? Cancer [Internet]. 2010 May 17;116(14):3378–88. Available from: http://onlinewiley.papi.cph.es/store/10.1002/cncr.25046/asset/25046_ftp.pdf?v=1&t=hfba295e&s=51da39562b0a3d8faffc9d9719c3d46e30fb830c .

Cited by 5 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3